Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923669 | 0.88 | USP2 (0.49) | ALDH1A1USP2TP53NPC1RAB9A | |
| SCHEMBL2923240 | 0.85 | F10 (0.43) | ALDH1A1USP2F10NPC1RAB9A | |
| SCHEMBL2914369 | 0.82 | CCNA2 (0.45) | ALDH1A1USP2TP53P2RX7SMN1; SMN2 | |
| SCHEMBL4232634 | 0.80 | ALDH1A1 (0.44) | ALDH1A1USP2TP53P2RX7F10 | |
| SCHEMBL2957861 | 0.78 | USP2 (0.41) | ALDH1A1USP2TP53F10RAB9A | |
| SCHEMBL2919290 | 0.75 | GAA (0.40) | ALDH1A1USP2F10NPC1RAB9A | |
| SCHEMBL2925302 | 0.75 | USP2 (0.45) | ALDH1A1USP2TP53F10RAB9A | |
| SCHEMBL2922601 | 0.72 | CCNA2 (0.48) | ALDH1A1TP53NPC1RAB9AGLA | |
| SCHEMBL2915969 | 0.72 | MAPT (0.44) | ALDH1A1USP2NPC1RAB9APKM | |
| SCHEMBL5226832 | 0.66 | PKM (0.60) | ALDH1A1TP53NPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | claimed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | claimed |
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | disclosed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-7531531-B2 | Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-05-12 | — | — | US | disclosed |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | ALDH1A1 4090/4885USP2 2428/4885TP53 779/4885 |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | ALDH1A1 4090/4885USP2 2428/4885TP53 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.